Zuzana Berecova, Dominik Juskanic, Martin Hazlinger, Marek Uhnak, Pavol Janega, Maros Rudnay, Robert Hatala
{"title":"CT quantification of COVID-19 pneumonia extent to predict individualized outcome.","authors":"Zuzana Berecova, Dominik Juskanic, Martin Hazlinger, Marek Uhnak, Pavol Janega, Maros Rudnay, Robert Hatala","doi":"10.4149/BLL_2024_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong> This study aimed to predict individual COVID-19 patient prognosis at hospital admission using artificial intelligence (AI)-based quantification of computed tomography (CT) pulmonary involvement.</p><p><strong>Background: </strong>Assessing patient prognosis in COVID-19 pneumonia is crucial for patient management and hospital and ICU organization.</p><p><strong>Methods: </strong>We retrospectively analyzed 559 patients with PCR-verified COVID-19 pneumonia referred to the hospital for a severe disease course. We correlated the CT extent of pulmonary involvement with patient outcome. We also attempted to define cut-off values of pulmonary involvement for predicting different outcomes.</p><p><strong>Results: </strong> CT-based disease extent quantification is an independent predictor of patient morbidity and mortality, with the prognosis being impacted also by age and cardiovascular comorbidities. With the use of explored cut-off values, we divided patients into three groups based on their extent of disease: (1) less than 28 % (sensitivity 65.4 %; specificity 89.1 %), (2) ranging from 28 % (31 %) to 47 % (sensitivity 87.1 %; specificity 62.7 %), and (3) above 47 % (sensitivity 87.1 %; specificity, 62.7 %), representing low risk, risk for oxygen therapy and invasive pulmonary ventilation, and risk of death, respectively.</p><p><strong>Conclusion: </strong>CT quantification of pulmonary involvement using AI-based software helps predict COVID-19 patient outcomes (Tab. 4, Fig. 4, Ref. 38).</p>","PeriodicalId":55328,"journal":{"name":"Bratislava Medical Journal-Bratislavske Lekarske Listy","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bratislava Medical Journal-Bratislavske Lekarske Listy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4149/BLL_2024_25","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This study aimed to predict individual COVID-19 patient prognosis at hospital admission using artificial intelligence (AI)-based quantification of computed tomography (CT) pulmonary involvement.
Background: Assessing patient prognosis in COVID-19 pneumonia is crucial for patient management and hospital and ICU organization.
Methods: We retrospectively analyzed 559 patients with PCR-verified COVID-19 pneumonia referred to the hospital for a severe disease course. We correlated the CT extent of pulmonary involvement with patient outcome. We also attempted to define cut-off values of pulmonary involvement for predicting different outcomes.
Results: CT-based disease extent quantification is an independent predictor of patient morbidity and mortality, with the prognosis being impacted also by age and cardiovascular comorbidities. With the use of explored cut-off values, we divided patients into three groups based on their extent of disease: (1) less than 28 % (sensitivity 65.4 %; specificity 89.1 %), (2) ranging from 28 % (31 %) to 47 % (sensitivity 87.1 %; specificity 62.7 %), and (3) above 47 % (sensitivity 87.1 %; specificity, 62.7 %), representing low risk, risk for oxygen therapy and invasive pulmonary ventilation, and risk of death, respectively.
Conclusion: CT quantification of pulmonary involvement using AI-based software helps predict COVID-19 patient outcomes (Tab. 4, Fig. 4, Ref. 38).
期刊介绍:
The international biomedical journal - Bratislava Medical Journal
– Bratislavske lekarske listy (Bratisl Lek Listy/Bratisl Med J) publishes
peer-reviewed articles on all aspects of biomedical sciences, including
experimental investigations with clear clinical relevance, original clinical
studies and review articles.